Department of Anesthesiology, University of California-San Diego, La Jolla, CA, USA.
Anesth Analg. 2012 Oct;115(4):797-804. doi: 10.1213/ANE.0b013e3182645dfd. Epub 2012 Jul 19.
Despite widespread use of chronic intrathecal (IT) infusions of morphine, there is little systematic human work evaluating the steady state morphine concentrations or cerebrospinal (CSF) chemistry after long-term IT morphine delivery. We sought to address these issues in patients receiving chronic IT morphine infusion.
Pain patients with implanted catheters and pumps (range: 127 to 2165 days), receiving a stable dosing (>1 week) of IT morphine by infusion, were entered into the study. The following sequence was performed: (1) estimation of pain score; (2) radiograph localization of catheter tip; (3) percutaneous sampling of lumbar CSF at the L4 to 5 or L5-S1 space. CSF/plasma samples were assayed for chemistry, and morphine and its 3/6 glucuronide metabolites (M3G, M6G) by liquid chromatography mass spectrometry.
Nineteen patients were enrolled. CSF samples were obtained from 16 subjects. Three patients were not included in the primary analysis because 1 catheter was epidural, 1 catheter was fractured, and 1 had a granuloma at the catheter tip. Of the 13 sampled patients, the range of daily doses, rates, and concentrations were 1.6 to 25 mg/d and 0.1 to 1 mL/d, 5 to 50 mg/mL, respectively. The principal observations were as follows: (i) morphine, M3G, and M6G were present in the CSF and plasma and showed a significant regression slope when plotted versus daily dose; (ii) in contrast, the regression slope of the group ratio morphine:M3G:M6G plotted versus daily dose in CSF or plasma was not different from zero; (iii) plotting "normalized" CSF analyte concentration (e.g., concentration at site/daily IT morphine dose) against the segmental distance of the sampling site from the catheter tip revealed a significant decline in concentration of morphine, but not of conjugates as a function of distance from the catheter tip; (iv) plotting CSF protein, glucose, and red and white cell counts versus daily morphine dose or morphine concentration at the sampling site revealed no significant regression; and (v) patients with a catheter failure or a granuloma showed reduced concentrations of morphine in their CSF.
Chronic infusion of morphine shows high concentrations, which correlate with the infusion dose and the proximity of the sampling site to the infusion site with no effects on CSF chemistry.
尽管慢性鞘内(IT)输注吗啡已广泛应用,但很少有系统的人体研究评估长期 IT 吗啡输注后的稳态吗啡浓度或脑脊液(CSF)化学。我们试图在接受慢性 IT 吗啡输注的患者中解决这些问题。
接受植入导管和泵的疼痛患者(范围:127 至 2165 天),通过输注稳定剂量(>1 周)的 IT 吗啡,进入研究。进行了以下顺序:(1)估计疼痛评分;(2)导管尖端的射线照相定位;(3)在 L4 到 5 或 L5-S1 空间进行经皮腰椎 CSF 采样。通过液相色谱-质谱法测定 CSF/血浆样本的化学物质、吗啡及其 3/6 葡萄糖醛酸代谢物(M3G、M6G)。
共纳入 19 例患者。16 例患者获得 CSF 样本。由于 1 例导管为硬膜外,1 例导管断裂,1 例导管尖端有肉芽肿,因此 3 例患者未纳入主要分析。在 13 例采样患者中,日剂量、速度和浓度范围分别为 1.6 至 25 mg/d 和 0.1 至 1 mL/d,5 至 50 mg/mL。主要观察结果如下:(i)吗啡、M3G 和 M6G 存在于 CSF 和血浆中,当与每日剂量作图时,显示出显著的回归斜率;(ii)相比之下,CSF 中吗啡:M3G:M6G 比值的回归斜率与每日剂量的比值或血浆中无差异;(iii)绘制“归一化”CSF 分析物浓度(例如,浓度/部位/每日 IT 吗啡剂量)与采样部位与导管尖端的节段距离之间的关系显示,吗啡浓度随距离导管尖端的距离呈显著下降,但与结合物浓度无关;(iv)绘制 CSF 蛋白、葡萄糖和红细胞与白细胞计数与每日吗啡剂量或采样部位吗啡浓度之间无显著回归;(v)导管故障或肉芽肿患者的 CSF 中吗啡浓度降低。
慢性输注吗啡显示出高浓度,与输注剂量和采样部位与输注部位的接近程度相关,对 CSF 化学无影响。